444 WEST LAKE STREET, SUITE 1700, CHICAGO, IL
MAIA Biotechnology, Inc. Holds 2026 Annual Meeting; Directors Re-elected
MAIA Biotechnology, Inc. Terminates At The Market Offering Agreement
Activates First U.S. Site for Ongoing International Phase 2 Expansion Trial of Novel Telomere Targeting Treatment Targeting Advanced Non-Small Cell Lung Cancer
Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer Therapy
Annual Report to Security Holders
Bonus Payments Approved for CEO Vlad Vitoc and Head of Finance Jeffrey Himmel...
Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer
Ex-99.1
Q1
FY 2025
Q3
Q2
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Notice of Exempt Offering of Securities
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload
Free Writing Prospectus